RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Samsung Biologics Co Stock

Samsung Biologics Co Revenue 2025

Samsung Biologics Co Revenue

5.75 T KRW

Ticker

207940.KS

ISIN

KR7207940008

WKN

A2AUB1

In 2025, Samsung Biologics Co's sales reached 5.75 T KRW, a 26.41% difference from the 4.55 T KRW sales recorded in the previous year.

The Samsung Biologics Co Revenue history

YEARREVENUE (T KRW)GROSS MARGIN (%)
2027e7.6929,81
2026e6.734,21
2025e5.7539,85
20244.5550,38
20233.6948,79
2022348,93
20211.5746,33
20201.1635,72
20190.727,37
20180.5427,09
20170.4628,37
20160.299,01
20150.09-25,75
20140.11-18,75
20130.02-217,74

Samsung Biologics Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Samsung Biologics Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Samsung Biologics Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Samsung Biologics Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Samsung Biologics Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Samsung Biologics Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Samsung Biologics Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Samsung Biologics Co’s growth potential.

Samsung Biologics Co Revenue, EBIT and net profit per share

DateSamsung Biologics Co RevenueSamsung Biologics Co EBITSamsung Biologics Co Net Income
2027e7.69 T undefined2.42 T undefined2.02 T undefined
2026e6.7 T undefined2.07 T undefined1.76 T undefined
2025e5.75 T undefined1.73 T undefined1.48 T undefined
20244.55 T undefined1.32 T undefined1.08 T undefined
20233.69 T undefined1.11 T undefined857.69 B undefined
20223 T undefined983.63 B undefined798.06 B undefined
20211.57 T undefined537.31 B undefined393.59 B undefined
20201.16 T undefined292.79 B undefined240.98 B undefined
2019701.59 B undefined91.74 B undefined202.9 B undefined
2018535.81 B undefined55.68 B undefined224.11 B undefined
2017464.63 B undefined65.98 B undefined-96.97 B undefined
2016294.62 B undefined-30.42 B undefined-176.82 B undefined
201591.28 B undefined-203.64 B undefined1.92 T undefined
2014105.15 B undefined-119.54 B undefined-95.91 B undefined
201317.12 B undefined-154.09 B undefined-135.59 B undefined

Samsung Biologics Co stock margins

The Samsung Biologics Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Samsung Biologics Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Samsung Biologics Co.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Samsung Biologics Co's sales revenue. A higher gross margin percentage indicates that the Samsung Biologics Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Samsung Biologics Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Samsung Biologics Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Samsung Biologics Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Samsung Biologics Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Samsung Biologics Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Samsung Biologics Co Margin History

Samsung Biologics Co Gross marginSamsung Biologics Co Profit marginSamsung Biologics Co EBIT marginSamsung Biologics Co Profit margin
2027e50.38 %31.46 %26.34 %
2026e50.38 %30.95 %26.23 %
2025e50.38 %30.03 %25.79 %
202450.38 %29.03 %23.82 %
202348.79 %30.14 %23.21 %
202248.93 %32.77 %26.59 %
202146.33 %34.27 %25.1 %
202035.72 %25.14 %20.69 %
201927.37 %13.08 %28.92 %
201827.09 %10.39 %41.83 %
201728.37 %14.2 %-20.87 %
20169.01 %-10.33 %-60.02 %
2015-25.75 %-223.1 %2,103.66 %
2014-18.75 %-113.69 %-91.21 %
2013-217.74 %-900.02 %-791.93 %

Samsung Biologics Co Aktienanalyse

What does Samsung Biologics Co do?

Samsung Biologics Co Ltd is a biotechnology company based in South Korea. The company was founded in 2011 by Samsung Group and has since become one of the world's leading providers of biopharmaceutical manufacturing services. Samsung Biologics aims to improve the conduct of clinical studies by providing top-quality biopharmaceutical products and services. The business model of Samsung Biologics is to manufacture biopharmaceuticals for internationally leading pharmaceutical and biotechnology companies. The company offers a wide range of services, including cell line development, process development, and production processes. Samsung Biologics Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Samsung Biologics Co's Sales Figures

The sales figures of Samsung Biologics Co originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Samsung Biologics Co’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Samsung Biologics Co's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Samsung Biologics Co’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Samsung Biologics Co stock

How much revenue did Samsung Biologics Co generate this year?

Samsung Biologics Co has achieved a revenue of 5.75 T KRW this year.

How much was the turnover of the company Samsung Biologics Co compared to the previous year?

The revenue of Samsung Biologics Co has increased by 26.41% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Samsung Biologics Co?

The revenue of Samsung Biologics Co is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Samsung Biologics Co measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Samsung Biologics Co so important for investors?

The revenue of Samsung Biologics Co is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Samsung Biologics Co pay?

Over the past 12 months, Samsung Biologics Co paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Samsung Biologics Co is expected to pay a dividend of 0 KRW.

What is the dividend yield of Samsung Biologics Co?

The current dividend yield of Samsung Biologics Co is .

When does Samsung Biologics Co pay dividends?

Samsung Biologics Co pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Samsung Biologics Co?

Samsung Biologics Co paid dividends every year for the past 0 years.

What is the dividend of Samsung Biologics Co?

For the upcoming 12 months, dividends amounting to 0 KRW are expected. This corresponds to a dividend yield of 0 %.

In which sector is Samsung Biologics Co located?

Samsung Biologics Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Samsung Biologics Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Samsung Biologics Co from 8/29/2025 amounting to 0 KRW, you needed to have the stock in your portfolio before the ex-date on 8/29/2025.

When did Samsung Biologics Co pay the last dividend?

The last dividend was paid out on 8/29/2025.

What was the dividend of Samsung Biologics Co in the year 2024?

In the year 2024, Samsung Biologics Co distributed 0 KRW as dividends.

In which currency does Samsung Biologics Co pay out the dividend?

The dividends of Samsung Biologics Co are distributed in KRW.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Samsung Biologics Co

Our stock analysis for Samsung Biologics Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Samsung Biologics Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.